Christopher C Oakes
Overview
Explore the profile of Christopher C Oakes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bhatnagar B, Kohlschmidt J, Orwick S, Buelow D, Fobare S, Oakes C, et al.
Blood Adv
. 2023 Aug;
7(16):4671-4675.
PMID: 37603350
No abstract available.
12.
Samayoa-Reyes G, Weigel C, Koech E, Waomba K, Jackson C, Onditi I, et al.
J Infect Dis
. 2023 Jul;
229(1):73-82.
PMID: 37433031
Background: The 2 cofactors in the etiology of Burkitt lymphoma (BL) are Epstein-Barr virus (EBV) and repeated Plasmodium falciparum malaria infections. This study evaluated EBV loads in mucosal and systemic...
13.
Ahmed E, Lustberg M, Hale C, Sloan S, Mao C, Zhang X, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37297008
Epstein-Barr virus (EBV) is a ubiquitous herpes virus associated with various cancers. EBV establishes latency with life-long persistence in memory B-cells and can reactivate lytic infection placing immunocompromised individuals at...
14.
Lutge A, Lu J, Hullein J, Walther T, Sellner L, Wu B, et al.
Haematologica
. 2023 May;
108(10):2664-2676.
PMID: 37226709
Understanding the molecular and phenotypic heterogeneity of cancer is a prerequisite for effective treatment. For chronic lymphocytic leukemia (CLL), recurrent genetic driver events have been extensively cataloged, but this does...
15.
Rebechi M, Kohlschmidt J, Mrozek K, Nicolet D, Mims A, Blachly J, et al.
Blood Adv
. 2023 May;
7(15):4019-4023.
PMID: 37196637
No abstract available.
16.
Lordo M, Stiff A, Oakes C, Mundy-Bosse B
J Leukoc Biol
. 2023 Mar;
113(5):518-524.
PMID: 36860165
Epigenetic therapy is an emerging field in the treatment of human cancer, including hematologic malignancies. This class of therapeutic agents approved by the US Food and Drug Administration for cancer...
17.
Mrozek K, Kohlschmidt J, Blachly J, Nicolet D, Carroll A, Archer K, et al.
Leukemia
. 2023 Feb;
37(4):788-798.
PMID: 36823396
Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017...
18.
Epperla N, Zhao Q, Anghelina M, Neal J, Blachly J, Rogers K, et al.
Am J Hematol
. 2023 Feb;
98(5):E116-E118.
PMID: 36808760
No abstract available.
19.
Andritsos L, Anghelina M, Neal J, Blachly J, Mathur P, Lele O, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3021-3031.
PMID: 36070610
Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder, comprising only 2% of all leukemias. The Hairy Cell Leukemia Foundation (HCLF) has developed a patient data registry to enable investigators...
20.
Merchand-Reyes G, Santhanam R, Robledo-Avila F, Weigel C, Ruiz-Rosado J, Mo X, et al.
J Immunol
. 2022 Aug;
209(6):1212-1223.
PMID: 35995507
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, but, despite advances in treatment, many patients still experience relapse. CLL cells depend on interactions with supportive cells, and nurse-like...